Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit

• المؤلفون الرئيسيون: Nickles, Emily, Dharmadhikari, Bhushan, Li, Yating, Walsh, Robert J, Koh, Liang Piu, Poon, Michelle, Tan, Lip Kun, Wang, Ling-Zhi, Ang, Yvonne, Asokumaran, Yugarajah, Chong, Wan Qin, Huang, Yiqing, Loh, Kwok Seng, Tay, Joshua, Soo, Ross, Koh, Mickey, Ho, Liam Pock, Chan, Marieta, Niam, Madelaine, Soh, Melissa, Luah, Yen Hoon, Lim, Chwee Ming, Kaliaperumal, Nivashini, Au, Veonice B, Talib, Najwa Binte Said Nasir, Sng, Reina, Connolly, John E, Goh, Boon Cher, Schwarz, Herbert
• مؤلفون آخرون: MEDICINE
• التنسيق: مقال
• اللغة: English
• منشور في: SPRINGER 2023
• الموضوعات: Science & Technology; Life Sciences & Biomedicine; Oncology; Immunology; Nasopharyngeal carcinoma; CD137L-DC; Dendritic cell immunotherapy; EBV; Phase 1 clinical trial; CD137 LIGAND; T-CELLS; LYMPHOCYTE-ACTIVATION; PHASE-II; MONOCYTE; IMMUNOTHERAPY; RECEPTOR; MEMBER; DIFFERENTIATION; PROLIFERATION
• الوصول للمادة أونلاين: https://scholarbank.nus.edu.sg/handle/10635/239112
• المؤسسة: National University of Singapore

10.1007/s00262-021-03075-3